Endocrine disorders associated with pediatric obesity

Handbook of Pediatric Obesity: Etiology, Pathophysiology, and Prevention

Volumn , Issue , 2016, Pages 135-155

  Ning, Cong ^a   Yanovski, Jack A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69349093493     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (190)

1. Hunter I, Greene SA, MacDonald TM, Morris AD. Prevalence and aetiology of hypothyroidism in the young. Arch Dis Child. 2000;83: 207-210.
2. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents. 1999-2000. JAMA. 2002;288: 1728-1732.
3. Krotkiewski M. Thyroid hormones in the pathogenesis and treatment of obesity. Eur J Pharmacol. 2002;440: 85-98.
4. Teng L, Bui H, Bachrach L, Lee P, Gagne N, Deal C, Wilson DM. Catch-up growth in severe juvenile hypothyroidism: treatment with a GnRH analog. J Pediatr Endocrinol Metab. 2004;17: 345-354.
5. Darendeliler F, Yildirim M, Bundak R, Sukur M, Saka N, Gunoz H. Growth of children with primary hypothyroidism on treatment with respect to different ages at diagnosis. J Pediatr Endocrinol Metab. 2001;14: 207-210.
6. Villabona C, Sahun M, Roca M, Mora J, Gomez N, Gomez JM, et al. Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med. Sci. 1999;318: 277-280.
7. Wheatley T, Edwards OM. Mild hypothyroidism and oedema: evidence for increased capillary permeability to protein. Clin Endocrinol (Oxf). 1983;18: 627-635.
8. Leijendekker WJ, van Hardeveld C, Elzinga G. Heat production during contraction in skeletal muscle of hypothyroid mice. Am J Physiol. 1987;253: E214-E220.
9. al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab.1997;82: 1118-1125.
10. Tagliaferri M, Berselli ME, Calo G, Minocci A, Savia G, Petroni ML, et al. Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile. Obes Res. 2001;9: 196-201.
11. Abbassi V, Rigterink E, Cancellieri RP. Clinical recognition of juvenile hypothyroidism in the early stage. Clin Pediatr (Phila). 1980;19: 782-786.
12. Hoogwerf BJ, Nuttall FQ. Long-term weight regulation in treated hyperthyroid and hypothyroid subjects. Am J Med. 1984;76: 963-970.
13. Pears J, Jung RT, Gunn A. Long-term weight changes in treated hyperthyroid and hypothyroid patients. Scott Med J. 1990;35: 180-182.
14. Chemaitilly W, Trivin C, Souberbielle JC, Brauner R. Assessing short-statured children for growth hormone deficiency. Horm Res. 2003;60: 34-42.
15. Meistas MT, Foster GV, Margolis S, Kowarski AA. Integrated concentrations of growth hormone, insulin C-peptide and prolactin in human obesity. Metabolism. 1982;31: 1224-1228.
16. Bell JP, Donald RA, Espiner EA. Pituitary response to insulin-induced hypoglycemia in obese subjects before and after fasting. J Clin Endocrinol Metab. 1970;31: 546-551.
17. Copinschi G, Wegienka LC, Hane S, Forsham PH. Effect of arginine on serum levels of insulin and growth hormone in obese subjects. Metabolism. 1967;16: 485-491.
18. Mims RB, Stein RB, Bethune JE. The effect of a single dose of L-dopa on pituitary hormones in acromegaly, obesity, and in normal subjects. J Clin Endocrinol Metab. 1973;37: 34-39.
19. Topper E, Gil-Ad I, Bauman B, Josefsberg Z, Laron Z. Plasma growth hormone response to oral clonidine as compared to insulin hypoglycemia in obese children and adolescents. Horm Metab Res. 1984;16(Suppl 1): 127-130.
20. Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW, Cowell CT. Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab. 2004;89: 81-86.
21. Dietz J, Schwartz J. Growth hormone alters lipolysis and hormone-sensitive lipase activity in 3T3-F442A adipocytes. Metabolism. 1991;40: 800-806.
22. Snel YE, Doerga ME, Brummer RJ, Zelissen PM, Zonderland ML, Koppeschaar HP. Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy. Eur J Endocrinol. 1995;133: 445-450.
23. Laron Z. Consequences of not treating children with laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab. 2001;14(Suppl 5): 1243-1248;discussion 1261-1262.
24. Gregory JW, Greene SA, Jung RT, Scrimgeour CM, Rennie MJ. Changes in body composition and energy expenditure after six weeks' growth hormone treatment. Arch Dis Child. 1991;66: 598-602.
25. Hoos MB, Westerterp KR, Gerver WJ. Short-term effects of growth hormone on body composition as a predictor of growth. J Clin Endocrinol Metab. 2003;88: 2569-2572.
26. Eden Engstrom B, Burman P, Holdstock C, Karlsson FA. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab. 2003;88: 5193-5198.
27. Cowan FJ, Evans WD, Gregory JW. Metabolic effects of discontinuing growth hormone treatment. Arch Dis Child. 1999;80: 517-523.
28. Kohno H, Ueyama N, Honda S. Unfavourable impact of growth hormone (GH) discontinuation on body composition and cholesterol profiles after the completion of height growth in GH-deficient young adults. Diabetes. Obes Metab. 1999;1: 293-296.
29. Tauber M, Jouret B, Cartault A, Lounis N, Gayrard M, Marcouyeux C, et al. Adolescents with partial growth hormone (GH) deficiency develop alterations of body composition after GH discontinuation and require follow-up. J Clin Endocrinol Metab. 2003;88: 5101-5106.
30. Block NE, Buse MG. Effects of hypercortisolemia and diabetes on skeletal muscle insulin receptor function in vitro and in vivo. Am J Physiol. 1989;256: E39-E48.
31. Naeser P. Effects of adrenalectomy on the obese-hyperglycemic syndrome in mice (gene symbol ob). Diabetologia. 1973;9: 376-379.
32. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology. 1999;140: 3188-3196.
33. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294: 2166-2170.
34. Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler GB, Jr., et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med. 1994;331:629-636.
35. Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, Wilson CB, Gitelman SE. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 1997;82: 3196-3202.
36. Lee PA, Weldon VV, Migeon CJ. Short stature as the only clinical sign of Cushing's syndrome. J Pediatr. 1975;86: 89-91.
37. Streeten DH, Faas FH, Elders MJ, Dalakos TG, Voorhess M. Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics. 1975;56: 797-803.
38. Lee PD, Winter RJ, Green OC. Virilizing adrenocortical tumors in childhood: eight cases and a review of the literature. Pediatrics. 1985;76: 437-444.
39. Gomez MT, Malozowski S, Winterer J, Vamvakopoulos NC, Chrousos GP. Urinary free cortisol values in normal children and adolescents. J Pediatr. 1991;118: 256-258.
40. Hindmarsh PC, Brook CG. Single dose dexamethasone suppression test in children: dose relationship to body size. Clin Endocrinol (Oxf). 1985;23: 67-70.
41. Jaksic T, Yaman M, Thorner P, Wesson DK, Filler RM, Shandling B. A 20-year review of pediatric pancreatic tumors. J Pediatr. Surg. 1992;27: 1315-1317.
42. Dolan JP, Norton JA. Occult insulinoma. Br J Surg. 2000;87: 385-387.
43. Stefanini P, Carboni M, Patrassi N, Basoli A. Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery. 1974;75: 597-609.
44. Harrington MG, McGeorge AP, Ballantyne JP, Beastall G. A prospective survey for insulinomas in a neurology department. Lancet. 1983;1: 1094-1095.
45. Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106: 307-310.
46. Hetherington AW. Hypothalamic lesions and adiposity in the rat. Anat Rec. 1940;78: 149-172.
47. Anand BK. Localization of feeding center in the hypothalamus of the rat. Proc Soc Exp Biol Med. 1951;11: 323-324.
48. Muller HL, Bueb K, Bartels U, Roth C, Harz K, Graf N, et al. Obesity after childhood craniopharyngioma -German multicenter study on pre-operative risk factors and quality of life. Klin Padiatr. 2001;213: 244-249.
49. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. Embo J. 2000;19: 1290-1300.
50. Nakagawa T, Ono-Kishino M, Sugaru E, Yamanaka M, Taiji M, Noguchi H. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Diabetes Metab Res Rev. 2002;18: 185-191.
51. Lawrence CB, Celsi F, Brennand J, Luckman SM. Alternative role for prolactin-releasing peptide in the regulation of food intake. Nat Neurosci. 2000;3: 645-646.
52. Lawrence CB, Ellacott KL, Luckman SM. PRL-releasing peptide reduces food intake and may mediate satiety signaling. Endocrinology. 2002;143: 360-367.
53. Roland BL, Sutton SW, Wilson SJ, Luo L, Pyati J, Huvar R, et al. Anatomical distribution of prolactinreleasing peptide and its receptor suggests additional functions in the central nervous system and periphery. Endocrinology. 1999;140: 5736-5745.
54. Lawrence CB, Williams T, Luckman SM. Intracerebroventricular galanin-like peptide induces different brain activation compared with galanin. Endocrinology. 2003;144: 3977-3984.
55. Degen L, Matzinger D, Drewe J, Beglinger C. The effect of cholecystokinin in controlling appetite and food intake in humans. Peptides. 2001;22: 1265-1269.
56. Donahey JC, van Dijk G, Woods SC, Seeley RJ. Intraventricular GLP-1 reduces short-but not longterm food intake or body weight in lean and obese rats. Brain Res. 1998;779: 75-83.
57. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418: 650-654.
58. Dourish CT, Rycroft W, Iversen SD. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors. Science. 1989;245: 1509-1511.
59. Kanse SM, Kreymann B, Ghatei MA, Bloom SR. Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett. 1988;241: 209-212.
60. Schwartz MW, Morton GJ. Obesity: keeping hunger at bay. Nature. 2002;418: 595-597.
61. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407: 908-913.
62. Wilcox BJ, Matsumoto AM, Dorsa DM, Baskin DG. Reduction of insulin binding in the arcuate nucleus of the rat hypothalamus after 6-hydroxydopamine treatment. Brain Res. 1989;500: 149-155.
63. Baskin DG, Wilcox BJ, Figlewicz DP, Dorsa DM. Insulin and insulin-like growth factors in the CNS. Trends Neurosci. 1988;11: 107-111.
64. Baura GD, Foster DM, Porte D, Jr Kahn SE, Bergman RN, Cobelli C, Schwartz MW. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest. 1993;92: 1824-1830.
65. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289: 2122-2125.
66. Tobe K, Suzuki R, Aoyama M, Yamauchi T, Kamon J, Kubota N, et al. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. J Biol Chem. 2001;276: 38337-38340.
67. Masaki T, Chiba S, Noguchi H, Yasuda T, Tobe K, Suzuki R, et al. Obesity in insulin receptor substrate-2-deficient mice: disrupted control of arcuate nucleus neuropeptides. Obes Res. 2004;12: 878-885.
68. Hoffman HJ, De Silva M, Humphreys RP, Drake JM, Smith ML, Blaser SI. Aggressive surgical management of craniopharyngiomas in children. J Neurosurg. 1992;76: 47-52.
69. Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA, et al. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab. 2003;88:611-616.
70. Sorva R. Children with craniopharyngioma. Early growth failure and rapid postoperative weight gain. Acta Paediatr Scand. 1988;77: 587-592.
71. Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW, Cowell CT. Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab.2004;89: 81-86.
72. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004;39: 909-914.
73. Harz KJ, Muller HL, Waldeck E, Pudel V, Roth C. Obesity in patients with craniopharyngioma:assessment of food intake and movement counts indicating physical activity. J Clin Endocrinol Metab.2003;88: 5227-5231.
74. Patel L, Cooper CD, Quinton ND, Butler GE, Gill MS, Jefferson IG, et al. Serum leptin and leptin binding activity in children and adolescents with hypothalamic dysfunction. J Pediatr. Endocrinol Metab. 2002;15: 963-971.
75. Tiosano D, Eisentein I, Militianu D, Chrousos GP, Hochberg Z. 11 Beta-hydroxysteroid dehydrogenase activity in hypothalamic obesity. J Clin Endocrinol Metab. 2003;88: 379-384.
76. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372: 425-432.
77. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol. 2002;13: 51-59.
78. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1: 1155-1161.
79. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-295.
80. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab. 1996;81: 4406-4413.
81. Ahren B, Mansson S, Gingerich RL, Havel PJ. Regulation of plasma leptin in mice: influence of age, high-fat diet, and fasting. Am J Physiol. 1997;273: R113-120.
82. Hassink SG, Sheslow DV, de Lancey E, Opentanova I, Considine RV, Caro JF. Serum leptin in children with obesity: relationship to gender and development. Pediatrics. 1996;98: 201-203.
83. Hickey MS, Israel RG, Gardiner SN, Considine RV, McCammon MR, Tyndall GL, et al. Gender differences in serum leptin levels in humans. Biochem Mol Med. 1996;59: 1-6.
84. Havel PJ, Kasim-Karakas S, Dubuc GR, Mueller W, Phinney SD. Gender differences in plasma leptin concentrations. Nat Med. 1996;2: 949-950.
85. Havel PJ. Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance. Proc Nutr Soc. 2000;59: 359-371.
86. Utriainen T, Malmstrom R, Makimattila S, Yki-Jarvinen H. Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. Diabetes. 1996;45: 1364-1366.
87. Saad MF, Khan A, Sharma A, Michael R, Riad-Gabriel MG, Boyadjian R, et al. Physiological insulinemia acutely modulates plasma leptin. Diabetes. 1998;47: 544-549.
88. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387: 903-908.
89. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18: 213-215.
90. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392: 398-401.
91. Farooqi IS, Keogh JM, Kamath S, Jones S, Gibson WT, Trussell R, et al. Partial leptin deficiency and human adiposity. Nature. 2001;414: 34-35.
92. Lahlou N, Issad T, Lebouc Y, Carel JC, Camoin L, Roger M, Girard J. Mutations in the human leptin and leptin receptor genes as models of serum leptin receptor regulation. Diabetes. 2002;51: 1980-1985.
93. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879-884.
94. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, et al. Phenotypic effects of leptin replacement on morbid obesity diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA. 2004;101: 4531-4536.
95. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110: 1093-1103.
96. Hagan MM, Rushing PA, Schwartz MW, Yagaloff KA, Burn P, Woods SC, et al. Role of the CNS melanocortin system in the response to overfeeding. J Neurosci. 1999;19: 2362-2367.
97. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med. 1999;5: 1066-1070.
98. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19:155-157.
99. Krude H, Gruters A. Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocrinol Metab. 2000;11:15-22.
100. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE, et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab.2003;88: 4633-4640.
101. Feng N, Adler-Wailes D, Elberg J, Chin JY, Fallon E, Carr A, et al. Sequence variants of the pomc gene and their associations with body composition in children. Obes Res. 2003;11: 619-24.
102. Echwald SM, Sorensen TI, Andersen T, Tybjaerg-Hansen A, Clausen JO, Pedersen O. Mutational analysis of the proopiomelanocortin gene in Caucasians with early onset obesity. Int J Obes Relat Metab Disord. 1999;23: 293-298.
103. Miraglia del Giudice E, Cirillo G, Santoro N, D'Urso L, Carbone MT, Di Toro R, Perrone L. Molecular screening of the proopiomelanocortin (POMC) gene in Italian obese children: report of three new mutations. Int J Obes Relat Metab Disord. 2001;25: 61-67.
104. Challis BG, Pritchard LE, Creemers JW, Delplanque J, Keogh JM, Luan J, et al. A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Hum Mol Genet. 2002;11:1997-2004.
105. Thomas L, Leduc R, Thorne BA, Smeekens SP, Steiner DF, Thomas G. Kex2-like endoproteases PC2 and PC3 accurately cleave a model prohormone in mammalian cells: evidence for a common core of neuroendocrine processing enzymes. Proc Natl Acad Sci USA. 1991;88: 5297-5301.
106. Benjannet S, Rondeau N, Day R, Chretien M, Seidah NG. PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad Sci USA. 1991;88: 3564-3568.
107. Dong W, Marcinkiewicz M, Vieau D, Chretien M, Seidah NG, Day R. Distinct mRNA expression of the highly homologous convertases PC5 and PACE4 in the rat brain and pituitary. J Neurosci. 1995;15:1778-1796.
108. Fricker LD, McKinzie AA, Sun J, Curran E, Qian Y, Yan L, et al. Identification and characterization of proSAAS, a granin-like neuroendocrine peptide precursor that inhibits prohormone processing. J Neurosci. 2000;20: 639-648.
109. Wei S, Feng Y, Che FY, Pan H, Mzhavia N, Devi LA, et al. Obesity and diabetes in transgenic mice expressing proSAAS. J Endocrinol. 2004;180: 357-368.
110. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet. 1997;16: 303-306.
111. Jackson RS, Creemers JW, Farooqi IS, Raffin-Sanson ML, Varro A, Dockray GJ, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest. 2003;112: 1550-1560.
112. Chen D, Garg A. Monogenic disorders of obesity and body fat distribution. J Lipid Res. 1999;40:1735-1746.
113. Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL, et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet. 1999;21: 119-122.
114. Fehm HL, Smolnik R, Kern W, McGregor GP, Bickel U, Born J. The melanocortin melanocytestimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab. 2001;86: 1144-1148.
115. Butler AA, Kesterson RA, Khong K, Cullen M.J, Pelleymounter MA, Dekoning J, et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology. 2000;141: 3518-3521.
116. Hinney A, Schmidt A, Nottebom K, Heibult O, Becker I, Ziegler A, et al. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab. 1999;84: 1483-1486.
117. Ho G, MacKenzie RG. Functional characterization of mutations in melanocortin-4 receptor associated with human obesity. J Biol Chem. 1999;274: 35816-35822.
118. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest. 2000;106: 253-262.
119. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348: 1085-1095.
120. Yeo GS, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci. 2004;7:1187-1189.
121. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 2003;6: 736-742.
122. Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH, et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci USA. 1999;96: 15239-15244.
123. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. Embo J. 2000;19: 1290-1300.
124. Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol. 2001;15:1748-17457.
125. Ono M, Ichihara J, Nonomura T, Itakura Y, Taiji M, Nakayama C, Noguchi H. Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice. Biochem Biophys Res Commun. 1997;238: 633-637.
126. Nakagawa T, Tsuchida A, Itakura Y, Nonomura T, Ono M, Hirota F, et al. Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. Diabetes. 2000;49: 436-444.
127. Nonomura T, Tsuchida A, Ono-Kishino M, Nakagawa T, Taiji M, Noguchi H. Brain-derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice. Int J Exp Diabetes Res. 2001;2: 201-209.
128. Nakagawa T, Ono-Kishino M, Sugaru E, Yamanaka M, Taiji M, Noguchi H. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Diabetes Metab Res Rev. 2002;18: 185-191.
129. Patten JL, Johns DR, Valle D, Eil C, Gruppuso PA, Steele G, et al. Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N Engl J Med. 1990;322: 1412-1419.
130. Miric A, Vechio JD, Levine MA. Heterogeneous mutations in the gene encoding the alpha-subunit of the stimulatory G protein of adenylyl cyclase in Albright hereditary osteodystrophy. J Clin Endocrinol Metab. 1993;76: 1560-1568.
131. Fitch N. Albright's hereditary osteodystrophy: a review. Am J Med. Genet. 1982;11: 11-29.
132. Mantovani G, Maghnie M, Weber G, De Menis E, Brunelli V, Cappa M, et al. Growth hormonereleasing hormone resistance in pseudohypoparathyroidism type ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab. 2003;88: 4070-4074.
133. Germain-Lee EL, Groman J, Crane JL, Jan de Beur SM, Levine MA. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab. 2003;88: 4059-4069.
134. Kaartinen JM, Kaar ML, Ohisalo JJ. Defective stimulation of adipocyte adenylate cyclase, blunted lipolysis, and obesity in pseudohypoparathyroidism 1a. Pediatr Res. 1994;35: 594-597.
135. Carel JC, Le Stunff C, Condamine L, Mallet E, Chaussain JL, Adnot P, et al. Resistance to the lipolytic action of epinephrine: a new feature of protein Gs deficiency. J Clin Endocrinol Metab. 1999;84:4127-4131.
136. Wang HY, Watkins DC, Malbon CC. Antisense oligodeoxynucleotides to GS protein alpha-subunit sequence accelerate differentiation of fibroblasts to adipocytes. Nature. 1992;358: 334-337.
137. Ong KK, Amin R, Dunger DB. Pseudohypoparathyroidism -another monogenic obesity syndrome. Clin Endocrinol (Oxf). 2000;52: 389-391.
138. Badano JL, Ansley SJ, Leitch CC, Lewis RA, Lupski JR, Katsanis N. Identification of a novel Bardet-Biedl syndrome protein BBS7, that shares structural features with BBS1 and BBS2. Am J Hum Genet. 2003;72: 650-658.
139. Mykytyn K, Braun T, Carmi R, Haider NB, Searby CC, Shastri M, et al. Identification of the gene that, when mutated, causes the human obesity syndrome BBS4. Nat Genet. 2001;28: 188-191.
140. Katsanis N, Beales PL, Woods MO, Lewis RA, Green JS, Parfrey PS, et al. Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. Nat Genet. 2000;26: 67-70.
141. Slavotinek AM, Stone EM, Mykytyn K, Heckenlively JR, Green JS, Heon E, et al. Mutations in MKKS cause Bardet-Biedl syndrome. Nat Genet. 2000;26: 15-16.
142. Nishimura DY, Searby CC, Carmi R, Elbedour K,Van Maldergem L, Fulton AB, et al. Positional cloning of a novel gene on chromosome 16q causing Bardet-Biedl syndrome (BBS2). Hum Mol Genet. 2001;10: 865-874.
143. Mykytyn K, Nishimura DY, Searby CC, Shastri M, Yen HJ, Beck JS, et al. Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. Nat Genet. 2002;31: 435-438.
144. Ansley SJ, Badano JL, Blacque OE, Hill J, Hoskins BE, Leitch CC, et al. Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature. 2003;425: 628-633.
145. Beales PL, Warner AM, Hitman GA, Thakker R, Flinter FA. Bardet-Biedl syndrome: a molecular and phenotypic study of 18 families. J Med Genet. 1997;34: 92-98.
146. Klein D, Ammann F. The syndrome of Laurence-Moon-Bardet-Biedl and allied diseases in Switzerland. Clinical, genetic and epidemiological studies. J Neurol Sci. 1969;9: 479-513.
147. Green JS, Parfrey PS, Harnett JD, Farid NR, Cramer BC, Johnson G, et al. The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome. N Engl J Med. 1989;321:1002-1009.
148. Farag TI, Teebi AS. High incidence of Bardet-Biedl syndrome among the Bedouin. Clin Genet. 1989;36: 463-464.
149. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet. 1999;36: 437-446.
150. Dekaban AS, Parks JS, Ross GT. Laurence-Moon syndrome: evaluation of endocrinological function and phenotypic concordance and report of cases. Med Ann Dist Columbia. 1972;41: 687-694.
151. Bauman ML, Hogan GR. Laurence-Moon-Biedl syndrome. Report of two unrelated children less than 3 years of age. Am J Dis Child. 1973;126: 119-126.
152. Hrynchak PK. Bardet-Biedl syndrome. Optom Vis Sci. 2000;77: 236-243.
153. O'Dea D, Parfrey PS, Harnett JD, Hefferton D, Cramer BC, Green J. The importance of renal impairment in the natural history of Bardet-Biedl syndrome. Am J Kidney Dis. 1996;27: 776-783.
154. Grace C, Beales P, Summerbell C, Jebb SA, Wright A, Parker D, Kopelman P. Energy metabolism in Bardet-Biedl syndrome. Int J Obes Relat Metab Disord. 2003;27: 1319-1324.
155. Croft JB, Swift M. Obesity, hypertension, and renal disease in relatives of Bardet-Biedl syndrome sibs. Am J Med. Genet. 1990;36: 37-42.
156. Croft JB, Morrell D, Chase CL, Swift M. Obesity in heterozygous carriers of the gene for the Bardet-Biedl syndrome. Am J Med. Genet. 1995;55: 12-15.
157. Fan Y, Rahman P, Peddle L, Hefferton D, Gladney N, Moore SJ, et al. Bardet-Biedl syndrome 1 genotype and obesity in the Newfoundland population. Int J Obes Relat Metab Disord. 2004;28:680-684.
158. Nicholls RD, Knepper JL. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet. 2001;2: 153-175.
159. Butler MG. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet. 1990;35: 319-332.
160. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics. 1993;91: 398-402.
161. Morgan JB, Rolles CJ. The nutrition and growth over a 10 month period of an infant with the Prader-Willi syndrome. Hum Nutr Appl Nutr. 1984;38: 304-307.
162. Bekx MT, Carrel AL, Shriver TC, Li Z, Allen DB. Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi Syndrome. J Pediatr. 2003;143: 372-376.
163. Burd L, Vesely B, Martsolf J, Kerbeshian J. Prevalence study of Prader-Willi syndrome in North Dakota. Am J Med. Genet. 1990;37: 97-99.
164. Smith A, Egan J, Ridley G, Haan E, Montgomery P, Williams K, Elliott E. Birth prevalence of Prader-Willi syndrome in Australia. Arch Dis Child. 2003;88: 263-264.
165. Vogels A, Van Den Ende J, Keymolen K, Mortier G, Devriendt K, Legius E, Fryns JP. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet. 2004;12: 238-240.
166. Zigman JM, Elmquist JK. Minireview: From anorexia to obesity -the yin and yang of body weight control. Endocrinology. 2003;144: 3749-3756.
167. Olszewski PK, Li D, Grace MK, Billington CJ, Kotz CM, Levine AS. Neural basis of orexigenic effects of ghrelin acting within lateral hypothalamus. Peptides. 2003;24: 597-602.
168. Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, et al. Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology. 2003;144: 1506-1512.
169. Faulconbridge LF, Cummings DE, Kaplan JM, Grill HJ. Hyperphagic effects of brainstem ghrelin administration. Diabetes. 2003;52: 2260-2265.
170. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000;141:4325-4328.
171. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86: 5992.
172. Haqq AM, Farooqi IS, O'Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88: 174-178.
173. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346: 1623-1630.
174. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol. 2001;145:669-673.
175. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med. 2002;8: 643-644.
176. Janssen JA, van der Toorn FM, Hofland LJ, van Koetsveld P, Broglio F, Ghigo E, et al. Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. Eur J Endocrinol. 2001;145: 711-716.
177. Hoybye C, Hilding A, Jacobsson H, Thoren M. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2003;58: 653-661.
178. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab. 2002;87: 1581-1585.
179. Myers SE, Davis A, Whitman BY, Santiago JV, Landt M. Leptin concentrations in Prader-Willi syndrome before and after growth hormone replacement. Clin Endocrinol (Oxf). 2000;52: 101-105.
180. Goldstone AP, Brynes AE, Thomas EL, Bell JD, Frost G, Holland A, et al. Resting metabolic rate, plasma leptin concentrations, leptin receptor expression, and adipose tissue measured by whole-body magnetic resonance imaging in women with Prader-Willi syndrome. Am J Clin Nutr. 2002;75:468-475.
181. Schoeller DA, Levitsky LL, Bandini LG, Dietz WW, Walczak A. Energy expenditure and body composition in Prader-Willi syndrome. Metabolism. 1988;37: 115-120.
182. Bueno G, Moreno LA, Pineda I, Campos J, Ruibal JL, Juste MG, et al. Serum leptin concentrations in children with Prader-Willi syndrome and non-syndromal obesity. J Pediatr Endocrinol Metab. 2000;13: 425-430.
183. Butler MG, Moore J, Morawiecki A, Nicolson M. Comparison of leptin protein levels in Prader-Willi syndrome and control individuals. Am J Med Genet. 1998;75: 7-12.
184. Mannens M, Alders M, Redeker B, Bliek J, Steenman M, Wiesmeyer C, et al. Positional cloning of genes involved in the Beckwith-Wiedemann syndrome, hemihypertrophy, and associated childhood tumors. Med Pediatr Oncol. 1996;27: 490-494.
185. Sotelo-Avila C, Gonzalez-Crussi F, Fowler JW. Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential. J Pediatr. 1980;96: 47-50.
186. Schneid H, Vazquez MP, Vacher C, Gourmelen M, Cabrol S, Le Bouc Y. The Beckwith-Wiedemann syndrome phenotype and the risk of cancer. Med Pediatr Oncol. 1997;28: 411-415.
187. Weksberg R, Nishikawa J, Caluseriu O, Fei YL, Shuman C, Wei C, et al. Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum Mol Genet. 2001;10: 2989-3000.
188. Takahashi K, Kobayashi T, Kanayama N. p57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblasts. Mol Hum Reprod. 2000;6: 1019-1025.
189. Sun FL, Dean WL, Kelsey G, Allen ND, Reik W. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature. 1997;389: 809-815.
190. Engel JR, Smallwood A, Harper A, Higgins MJ, Oshimura M, Reik W, et al. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet. 2000;37: 921-926.